ALDH1L1 and diffuse large B-cell lymphoma: Moreover, ALDH1L1 expression may represent a predictive biomarker for response to polatuzumab, potentially in combination with other markers such as ABCG2, a well‐characterized ATP‐binding cassette transporter that was strongly upregulated in polatuzumab‐resistant DLBCL cell lines.